Cervical Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV031 MIFTS: 54	Cervical Adenocarcinoma Categories: Cancer diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma ¹² ⁵⁹ ⁵⁵ ¹⁵ ⁷³

Adenocarcinoma of the Uterine Cervix ¹²

Adenocarcinoma of the Cervix Uteri ⁵⁹

Adenocarcinoma Cervix Uteri ¹²

Adenocarcinoma of Cervix ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Endocervix

Malignant neoplasm: Exocervix

Malignant neoplasm: Overlapping lesion of cervix uteri

Orphanet: ⁵⁹

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:3702

NCIt ⁵⁰ C4029

Orphanet ⁵⁹ ORPHA213772

UMLS via Orphanet ⁷⁴ C0279672

ICD10 via Orphanet ³⁴ C53.0 C53.1 C53.8

UMLS ⁷³ C0279672

Sources

Summaries for Cervical Adenocarcinoma

Disease Ontology : ¹² A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to glassy cell carcinoma of the cervix and adenocarcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Glioma. The drugs Gardasil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and ovary, and related phenotypes are cellular and homeostasis/metabolism

Sources

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)

#	Related Disease	Score	Top Affiliating Genes
1	glassy cell carcinoma of the cervix	32.5	ERBB2 ESR1 PGR
2	adenocarcinoma	31.4	CDKN2A ERBB2 PTGS2 TP53
3	adenocarcinoma in situ	30.9	CDKN2A CDX2 KRT20 KRT7
4	mucinous adenocarcinoma	30.8	CDKN2A CDX2 KRT20 KRT7
5	papillary transitional carcinoma	30.4	KRT20 KRT7
6	endocervical adenocarcinoma	30.4	CDKN2A CDX2 KRT20 KRT7 TP53
7	papillary serous adenocarcinoma	30.4	KRT20 KRT7 PGR TP53
8	signet ring cell adenocarcinoma	30.4	CDX2 KRT20 KRT7
9	squamous cell carcinoma	30.3	CDKN2A ERBB2 PTGS2 TP53
10	endometriosis	30.1	ESR1 PGR PTGS2
11	cervical squamous cell carcinoma	29.8	CDKN2A RASSF1 TP53
12	transitional cell carcinoma	29.7	CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
13	suppressor of tumorigenicity 3	29.7	CDKN1A CDKN2A TP53
14	small cell carcinoma	29.6	CDKN2A KRT20 KRT7 TP53
15	papillary adenocarcinoma	29.5	ERBB2 KRT7 PGR TP53
16	vulval paget's disease	29.5	CDKN2A ERBB2 KRT20 KRT7
17	gastric cancer	29.4	CDKN1A CDKN2A CDX2 ERBB2 KRT20 PTGS2
18	papilloma	29.4	CDKN1A CDKN2A KRT20 KRT7 TP53
19	ovarian cancer 1	29.4	ERBB2 KRT7 TP53
20	lung cancer	28.8	CDKN1A CDKN2A ERBB2 KRT20 KRT7 PTGS2
21	endometrial cancer	28.6	CDKN1A CDKN2A EBAG9 ERBB2 ESR1 KRT7
22	early invasive cervical adenocarcinoma	12.5
23	cervical mucinous adenocarcinoma	11.1
24	cervical clear cell adenocarcinoma	11.1
25	wolffian duct adenocarcinoma	11.1
26	cervical serous adenocarcinoma	11.1
27	cervical endometrioid adenocarcinoma	11.1
28	balanitis xerotica obliterans	10.3	CDKN2A PTGS2
29	bile reflux	10.3	CDX2 PTGS2
30	bowenoid papulosis	10.3	CDKN2A PTGS2
31	vaginal benign neoplasm	10.3	CDX2 KRT20
32	inverted transitional papilloma	10.3	CDKN2A KRT7
33	vaginal adenoma	10.3	CDX2 KRT20
34	duodenum adenocarcinoma	10.3	CDX2 KRT7
35	ovary neuroendocrine neoplasm	10.3	CDX2 KRT7
36	anus adenocarcinoma	10.3	CDX2 KRT7
37	large intestine adenocarcinoma	10.3	KRT20 KRT7
38	vaginal tubulovillous adenoma	10.3	CDX2 KRT20
39	bladder lymphoma	10.3	KRT20 KRT7
40	epithelial predominant wilms' tumor	10.3	CDX2 KRT7
41	seminal vesicle adenocarcinoma	10.3	KRT20 KRT7
42	transverse colon cancer	10.3	KRT20 KRT7
43	vulva squamous cell carcinoma	10.3	CDKN2A TP53
44	scrotal carcinoma	10.3	CDKN2A TP53
45	bladder squamous cell carcinoma	10.3	CDKN2A TP53
46	linitis plastica	10.3	KRT20 KRT7
47	bile duct cystadenocarcinoma	10.3	KRT20 KRT7
48	cystic basal cell carcinoma	10.3	KRT20 KRT7
49	malignant syringoma	10.3	KRT20 KRT7
50	keratinizing squamous cell carcinoma	10.3	CDKN2A TP53

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:

Sources

Symptoms & Phenotypes for Cervical Adenocarcinoma

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

⁴⁶ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.31	CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
2	homeostasis/metabolism	MP:0005376	10.26	CDKN1A CDKN2A CDX2 ERBB2 ESR1 KRT7
3	cardiovascular system	MP:0005385	10.23	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
4	digestive/alimentary	MP:0005381	10.21	CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2
5	endocrine/exocrine gland	MP:0005379	10.19	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
6	immune system	MP:0005387	10.16	CDKN1A CDKN2A EBAG9 ESR1 LAMC2 PGR
7	embryo	MP:0005380	10.15	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
8	integument	MP:0010771	10.1	CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PGR
9	neoplasm	MP:0002006	10.06	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
10	limbs/digits/tail	MP:0005371	10.02	CDKN1A CDX2 ERBB2 ESR1 LAMC2 PGR
11	muscle	MP:0005369	9.98	CDKN1A CDKN2A ERBB2 ESR1 PGR PTGS2
12	liver/biliary system	MP:0005370	9.93	CDKN1A CDKN2A ESR1 PTGS2 RASSF1 TP53
13	normal	MP:0002873	9.92	CDX2 ERBB2 ESR1 PGR PTGS2 RASSF1
14	no phenotypic analysis	MP:0003012	9.85	CDKN1A CDKN2A ESR1 PGR PTGS2 TP53
15	reproductive system	MP:0005389	9.76	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
16	renal/urinary system	MP:0005367	9.73	CDKN1A ESR1 KRT7 LAMC2 PTGS2 TP53
17	respiratory system	MP:0005388	9.5	CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
18	skeleton	MP:0005390	9.28	CDKN1A CDKN2A CDX2 ERBB2 ESR1 LAMC2

Sources

Drugs & Therapeutics for Cervical Adenocarcinoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Gardasil ¹⁸ ⁴⁹	quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine	Merck	June 2006
FDA Label: Gardasil Disease/s that Drug Treats:Cervical Cancer Caused by Human Papillomavirus Indications and Usage: ¹⁸ GARDASIL is a vaccine indicated in girls and women 9 through 26years of age for the prevention of the following diseases caused byHuman Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16and 18 (1.1) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.1)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Cervical intraepithelial neoplasia (CIN) grade 2/3 and Cervicaladenocarcinoma in situ (AIS) (1.1) Cervical intraepithelial neoplasia (CIN) grade 1 (1.1) Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 (1.1) Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 (1.1) Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3 (1.1)GARDASIL is indicated in boys and men 9 through 26 years of age forthe prevention of the following diseases caused by HPV types includedin the vaccine: Anal cancer caused by HPV types 16 and 18 (1.2) Genital warts (condyloma acuminata) caused by HPV types 6 and11 (1.2)And the following precancerous or dysplastic lesions caused by HPVtypes 6, 11, 16, and 18: Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3. (1.2)Limitations of GARDASIL Use and Effectiveness: GARDASIL does not eliminate the necessity for women tocontinue to undergo recommended cervical cancer screening.(1.3, 17) Recipients of GARDASIL should not discontinue anal cancerscreening if it has been recommended by a health care provider.(1.3, 17) GARDASIL has not been demonstrated to provide protectionagainst disease from vaccine and non-vaccine HPV types to whicha person has previously been exposed through sexual activity.(1.3, 14.4, 14.5) GARDASIL is not intended to be used for treatment of activeexternal genital lesions; cervical, vulvar, vaginal, and analcancers; CIN; VIN; VaIN, or AIN. (1.3) GARDASIL has not been demonstrated to protect againstdiseases due to HPV types not contained in the vaccine. (1.3,14.4, 14.5) Not all vulvar, vaginal, and anal cancers are caused by HPV, andGARDASIL protects only against those vulvar, vaginal, and analcancers caused by HPV 16 and 18. (1.3) GARDASIL does not protect against genital diseases not causedby HPV. (1.3) Vaccination with GARDASIL may not result in protection in allvaccine recipients. (1.3) GARDASIL has not been demonstrated to prevent HPV-relatedCIN 2/3 or worse in women older than 26 years of age. (14.7) DrugBank Targets: - Mechanism of Action: ¹⁸ Target: humoral immune response Action: inducer FDA: HPV only infects human beings. Animal studies with analogous animal papillomaviruses suggest thatthe efficacy of L1 VLP vaccines may involve the development of humoral immune responses. Humanbeings develop a humoral immune response to the vaccine, although the exact mechanism of protectionis unknown.

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Cisplatin

Approved

Phase 4,Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Vaccines

Phase 4,Phase 3,Phase 2

Epoetin alfa

Phase 4,Phase 3

113427-24-0

Hematinics

Phase 4,Phase 3

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Topotecan

Approved, Investigational

Phase 3,Phase 2,Phase 1

123948-87-8, 119413-54-6

60700

Bevacizumab

Approved, Investigational

Phase 3,Phase 2

216974-75-3

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

60780 44424639

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1

95058-81-4

60750

Vinblastine

Approved

Phase 3

865-21-4

241903 13342

Vindesine

Approved, Investigational

Phase 3

59917-39-4, 53643-48-4

40839

leucovorin

Approved

Phase 3,Phase 2

58-05-9

6006 143

Fluorouracil

Approved

Phase 3,Phase 1,Phase 2

51-21-8

3385

Bleomycin

Approved, Investigational

Phase 3

11056-06-7

5360373

Methotrexate

Approved

Phase 3

59-05-2, 1959-05-2

126941

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2

59-30-3

6037

Tirapazamine

Investigational

Phase 3,Phase 1

27314-97-2

Immunologic Factors

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Antibodies, Monoclonal

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Albumin-Bound Paclitaxel

Phase 3,Phase 2,Phase 1

Anti-Infective Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antiviral Agents

Phase 3,Phase 2,Phase 1

Angiogenesis Inhibitors

Phase 3,Phase 2

Immunoglobulin G

Phase 3,Phase 2

topoisomerase I inhibitors

Phase 3,Phase 2,Phase 1

Endothelial Growth Factors

Phase 3,Phase 2

Mitogens

Phase 3,Phase 2

Angiogenesis Modulating Agents

Phase 3,Phase 2

Topoisomerase Inhibitors

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Isophosphamide mustard

Phase 3

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2

Folic Acid Antagonists

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2

Vitamin B Complex

Phase 3,Phase 2

Vitamin B9

Phase 3,Phase 2

Antirheumatic Agents

Phase 3,Phase 1,Phase 2

Dermatologic Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3,Phase 2

Folate

Phase 3,Phase 2

Mitomycins

Phase 3

Interventional clinical trials:

(show top 50) (show all 97)

#	Name	Status	NCT ID	Phase	Drugs
1	V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)	Completed	NCT01544478	Phase 4
2	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer	Completed	NCT00046969	Phase 4	cisplatin
3	Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)	Completed	NCT00834106	Phase 3
4	Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
5	Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
6	Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer	Completed	NCT00003209	Phase 3	cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
7	Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer	Completed	NCT00003945	Phase 3	cisplatin;topotecan hydrochloride
8	Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia	Completed	NCT00017004	Phase 3	Cisplatin
9	Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix	Completed	NCT00003078	Phase 3	cisplatin;fluorouracil
10	Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer	Recruiting	NCT02853604	Phase 3	ADXS11-001;Placebo
11	Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery	Recruiting	NCT01101451	Phase 3	Cisplatin
12	Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy	Recruiting	NCT00980954	Phase 3	carboplatin;cisplatin;paclitaxel
13	A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)	Active, not recruiting	NCT03493542	Phase 3
14	Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer	Active, not recruiting	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
15	Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer	Active, not recruiting	NCT00039338	Phase 3	cisplatin
16	Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer	Active, not recruiting	NCT01672892	Phase 3
17	Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix	Terminated	NCT00054067	Phase 3	cisplatin
18	Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
19	Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer	Terminated	NCT00085631	Phase 3	cisplatin
20	Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer	Unknown status	NCT00008112	Phase 2	cisplatin
21	Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer	Unknown status	NCT01158248	Phase 2	cisplatin
22	Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer	Unknown status	NCT00462397	Phase 2	carboplatin;cisplatin;paclitaxel
23	Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application	Completed	NCT01639625	Phase 2	CIGB300
24	Ixabepilone to Treat Cervical Cancer	Completed	NCT00924066	Phase 2	Ixempra (Ixabepilone (BMS-247550) )
25	Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00039442	Phase 2	Capecitabine
26	Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer	Completed	NCT02562729	Phase 2
27	Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL	Completed	NCT01957878	Phase 2
28	Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery	Completed	NCT00389974	Phase 2	sunitinib malate
29	ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
30	Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
31	Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer	Completed	NCT00002562	Phase 2	paclitaxel
32	Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer	Completed	NCT00005999	Phase 2	arsenic trioxide
33	Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
34	Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer	Completed	NCT00005070	Phase 2	irofulven
35	Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix	Completed	NCT00003017	Phase 2
36	Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer	Completed	NCT00002916	Phase 2
37	Topotecan and Paclitaxel in Treating Patients With Recurrent or Metastatic Cancer of the Cervix	Completed	NCT00003065	Phase 2	paclitaxel;topotecan hydrochloride
38	Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
39	Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery	Completed	NCT01026792	Phase 2	Temsirolimus
40	FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer	Completed	NCT00559377	Phase 2
41	Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
42	Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer	Completed	NCT00369122	Phase 2	Cisplatin
43	Carboplatin and Paclitaxel With or Without Cediranib Maleate in Treating Patients With Metastatic or Recurrent Cervical Cancer That Cannot Be Removed by Surgery	Completed	NCT01229930	Phase 2	carboplatin;cediranib maleate;paclitaxel
44	Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer	Completed	NCT00807079	Phase 1, Phase 2	carboplatin;topotecan hydrochloride
45	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage IB, Stage II, or Stage IIIB Cervical Cancer	Completed	NCT00957411	Phase 2	cisplatin
46	Radiation Therapy and Cisplatin With or Without Amifostine for Patients With Stage IIIB or IVA Cervical Cancer	Completed	NCT00012012	Phase 1, Phase 2	Amifostine trihydrate;Cisplatin
47	Radiation Therapy in Treating Patients With Cervical Cancer	Completed	NCT00278304	Phase 2
48	Cetuximab and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer	Completed	NCT00101192	Phase 2	cisplatin
49	Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer	Completed	NCT01590017	Phase 2	cisplatin
50	Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer	Completed	NCT00276796	Phase 2	cisplatin;paclitaxel;topotecan hydrochloride

Search NIH Clinical Center for Cervical Adenocarcinoma

Sources

Genetic Tests for Cervical Adenocarcinoma

Sources

Anatomical Context for Cervical Adenocarcinoma

MalaCards organs/tissues related to Cervical Adenocarcinoma:

⁴¹

Cervix, Lymph Node, Ovary, T Cells, Colon, Lung, Breast

Sources

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 542)

#	Title	Authors	Year
1	Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. ( 29474242 )	Sar A....Duggan M.A.	2018
2	Uterine cervical adenocarcinoma associated with lobular endocervical glandular hyperplasia: Radiologic-pathologic correlation. ( 29144012 )	Ohya A....Kadoya M.	2018
3	Morphologic Features of Gastric-type Cervical Adenocarcinoma in Small Surgical and Cytology Specimens. ( 29750702 )	Turashvili G....Murali R.	2018
4	Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001). ( 29341491 )	Okonogi N....Shozu M.	2018
5	miR-27a inhibits cervical adenocarcinoma progression by downregulating the TGF-I^RI signaling pathway. ( 29531222 )	Fang F....Wang Z.	2018
6	Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. ( 29362924 )	Xu H.Y....Hua K.	2018
7	Postoperative clinicopathological factors affecting cervical adenocarcinoma: Stages I-IIB. ( 29480826 )		2018
8	Concomitant endometrial and cervical adenocarcinoma: A case report and literature review. ( 29505548 )		2018
9	MiR-362-3p functions as a tumor suppressor through targeting MCM5 in cervical adenocarcinoma. ( 29871972 )		2018
10	The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. ( 29876746 )		2018
11	Pretreatment neutrophil to lymphocyte and platelet to lymphocyte ratios as predictive factors for the survival of cervical adenocarcinoma patients. ( 30538552 )	Jonska-Gmyrek J...Kotowicz B	2018
12	Molecular prognostic factors in early-stage cervical adenocarcinoma. ( 30509055 )	Bodzek M...Lackowska B	2018
13	Trefoil factor family 2 protein: a potential immunohistochemical marker for aiding diagnosis of lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. ( 30324235 )	Asaka S...Ota H	2018
14	Effect of tibolone on the survival of early stage cervical adenocarcinoma patients. ( 30254994 )	Lee SH...Lee KB	2018
15	RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? ( 30284744 )	Powell A...Blomfield P	2018
16	Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression. ( 30227306 )	Akimoto T...Sawada N	2018
17	Bioinformatics analysis of methylation in cervical adenocarcinoma in Xinjiang, China. ( 30170437 )	Yuan M...Abulizi G	2018
18	Survival benefits with the addition of adjuvant hysterectomy to radiochemotherapy for treatment of stage I-II adenocarcinoma of the uterine cervix. ( 30114328 )	Huang XB...Zhou J	2018
19	Disease-free survival after robotic-assisted laparoscopic total pelvic exenteration for recurrent cervical adenocarcinoma: A case report. ( 30045297 )	Yang Q...Xiao L	2018
20	Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest. ( 30100745 )	Li XQ...He RX	2018
21	Surgical treatment and outcome of early invasive adenocarcinoma of the uterine cervix (FIGO stage IA1). ( 28429457 )	Yahata H...Kato K	2018
22	The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix. ( 29404709 )	Roma AA...Fadare O	2018
23	Gastric-Type Adenocarcinoma of the Uterine Cervix: Magnetic Resonance Imaging Features, Clinical Outcomes, and Prognostic Factors. ( 29683881 )	Park KJ...Cho KS	2018
24	Is the ovarian preservation safe in young women with stages IB-IIA villoglandular adenocarcinoma of the uterine cervix? ( 29770624 )	Ju UC...Kim SM	2018
25	Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study. ( 29848719 )	Gadducci A...Sartori E	2018
26	Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma. ( 28331901 )	Deshmukh U....Azodi M.	2017
27	Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. ( 28102052 )	van der Horst J....de Kok I.M.	2017
28	Projected impact of HPV vaccination and primary HPV screening on cervical adenocarcinoma: Example from Australia. ( 28720447 )	Smith M.A....Canfell K.	2017
29	Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells. ( 29067110 )	Takiguchi E....Irahara M.	2017
30	Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study. ( 29027399 )	Wu S.G....Zhou J.	2017
31	Risk of persistent or recurrent neoplasia in conservatively treated women with cervical adenocarcinoma in situ with negative histological margins. ( 28181670 )	Munro A....Cohen P.A.	2017
32	Tumor-associated CD204<sup>+</sup>M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinoma. ( 29274107 )	Kawachi A....Hiraoka N.	2017
33	Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. ( 28644686 )	Pirog E.C.	2017
34	Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells. ( 28249781 )	Zhang F....Wei Z.J.	2017
35	Methods for Measuring and Staging a Uterine Cervical Adenocarcinoma Showing Intracystic Papillary Growth: A Case Report. ( 28700431 )	Yoshida H....Kato T.	2017
36	Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multicenter retrospective study of 105 patients. ( 28631536 )	Hu J....Zhu L.	2017
37	Immunohistochemical Expression of the Tumor Suppressor Protein p16INK4a in Cervical Adenocarcinoma. ( 28245508 )		2017
38	Excisional treatment in women with cervical adenocarcinoma in situ (AIS): a prospective randomised controlled non-inferiority trial to compare AIS persistence/recurrence after loop electrosurgical excision procedure with cold knife cone biopsy: protocol for a pilot study. ( 28851799 )		2017
39	Metastatic cervical adenocarcinoma to the orbital subperiosteal space. ( 28457305 )		2017
40	Cervical Adenocarcinoma Has a Poorer Prognosis and a Higher Propensity for Distant Recurrence Than Squamous Cell Carcinoma. ( 28604449 )		2017
41	Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ (ACIS): A Systematic Review and Meta-Analysis. ( 28125627 )	Jiang Y...Li L	2017
42	Role of positive peritoneal cytology in FIGO stage IB to IIB cervical adenocarcinoma. ( 28186628 )	Han Y...Wu L	2017
43	Cervical adenocarcinoma generator of procoagulant status and ischemic stroke. ( 29556644 )	Bumbea AM...Mu?etescu AE	2017
44	The effect of local treatment modalities in patients with early-stage adenocarcinoma of the uterine cervix: A population-based analysis. ( 28302450 )	Zhou J...He ZY	2017
45	Ovarian preservation in adenocarcinoma of the uterine cervix. ( 28738842 )	Zhou J...Lou H	2017
46	The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervix. ( 28761376 )	Zhou J...Chen QH	2017
47	Lack of Significant Effects of Chlamydia trachomatis Infection on Cervical Adenocarcinoma Risk: Nested Case-Control Study. ( 27227411 )	Smelov V....Dillner J.	2016
48	Incidence and survival trends of cervical adenocarcinoma in Italy: Cytology screening has become more effective in downstaging the disease but not in detecting its precursors. ( 27639249 )	Mancini S....Bucchi L.	2016
49	Analysis of the expression and localization of tight junction transmembrane proteins, claudin-1, -4, -7, occludin and JAM-A, in human cervical adenocarcinoma. ( 26847087 )	Akimoto T....Sawada N.	2016
50	The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. ( 27554015 )	Chen W....Qiao Y.	2016

Sources

Genes for Cervical Adenocarcinoma

Genes related to Cervical Adenocarcinoma (0 elite genes):

(show all 15)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	30.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14501820 18156982 18202755 (more) 16462152 19762530 11499840 9038270 10202666 15041997
2	KRT7	Keratin 7	Protein Coding	29.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14632574 19762530
3	CDX2	Caudal Type Homeobox 2	Protein Coding	28.6	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	14632574 18156982 19762530
4	KRT20	Keratin 20	Protein Coding	28.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	18156982 19762530 14632574
5	ESR1	Estrogen Receptor 1	Protein Coding	26.53	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	8319181 1457356 12647218 (more) 9028361 9635534 10202666 10727981 17354237
6	RASSF1	Ras Association Domain Family Member 1	Protein Coding	25.58	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17360030 12702579
7	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	24.04	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20524403 11248419 11499840 (more) 10202666 15041997
8	TP53	Tumor Protein P53	Protein Coding	21.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	LAMC2	Laminin Subunit Gamma 2	Protein Coding	21.83	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	16343183
10	EBAG9	Estrogen Receptor Binding Site Associated, Antigen, 9	Protein Coding	21.1	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17981616 11104614
11	ZNF582	Zinc Finger Protein 582	Protein Coding	20.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	20.75	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	20.7	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	VIL1	Villin 1	Protein Coding	20.55	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	PGR	Progesterone Receptor	Protein Coding	20.45	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8319181 8144142 9028361 (more) 10727981 17354237

Sources

Variations for Cervical Adenocarcinoma

Sources

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Sources

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 23)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.84	CDKN1A ERBB2 LAMC2 PTGS2 TP53
2	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.52	CDKN1A CDKN2A ERBB2 ESR1 RASSF1 TP53
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.37	CDKN1A CDKN2A CDX2 ERBB2 ESR1 PGR
4	MicroRNAs in cancer ³⁷	12.21	CDKN1A CDKN2A ERBB2 PTGS2 RASSF1 TP53
5	Proteoglycans in cancer ³⁷	12.15	CDKN1A ERBB2 ESR1 TP53
6	Cell cycle Role of SCF complex in cell cycle regulation ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Regulation of G1/S transition (part 1) ²² Immune response MIF-JAB1 signaling ²²	12.04	CDKN1A CDKN2A ESR1 PGR
7	Pathways in cancer ³⁷	11.95	CDKN1A CDKN2A ERBB2 ESR1 LAMC2 PTGS2
8	Interleukin-4 and 13 signaling ⁶⁶	11.84	CDKN1A PTGS2 TP53
9	Glioblastoma Multiforme ⁶⁴	11.83	CDKN1A CDKN2A TP53
10	DNA Damage Response (only ATM dependent) ¹	11.82	CDKN1A CDKN2A ERBB2 TP53
11	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ¹ Nuclear signaling by ERBB4 ⁶⁶	11.8	ERBB2 ESR1 PGR
12	Senescence and Autophagy in Cancer ¹	11.79	CDKN1A CDKN2A TP53
13	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors ⁶⁶ Show member pathways Activation of the TFAP2 (AP-2) family of transcription factors ⁶⁶ Negative regulation of activity of TFAP2 (AP-2) family transcription factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of cell cycle factors ⁶⁶ TFAP2 (AP-2) family regulates transcription of growth factors and their receptors ⁶⁶ TFAP2 (AP-2) family regulates transcription of other transcription factors ⁶⁶ TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation ⁶⁶	11.71	CDKN1A ERBB2 ESR1
14	Small cell lung cancer ³⁷	11.67	CDKN1A LAMC2 PTGS2 TP53
15	Platinum drug resistance ³⁷	11.49	CDKN1A CDKN2A ERBB2 TP53
16	Hepatitis C and Hepatocellular Carcinoma ¹	11.42	CDKN1A PTGS2 TP53
17	Photodynamic therapy-induced AP-1 survival signaling. ¹	11.41	CDKN1A CDKN2A TP53
18	Aryl Hydrocarbon Receptor ¹	11.37	CDKN1A ESR1 PTGS2
19	Bladder cancer ³⁷ ¹	11.22	CDKN1A CDKN2A ERBB2 RASSF1 TP53
20	Signaling mediated by p38-alpha and p38-beta ¹	11.2	ESR1 PTGS2 TP53
21	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.95	CDKN1A CDKN2A TP53
22	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.66	CDKN1A TP53
23	Transcriptional activation of p53 responsive genes ⁶⁶ Show member pathways Transcriptional activation of cell cycle inhibitor p21 ⁶⁶	10.46	CDKN1A TP53

Sources

GO Terms for Cervical Adenocarcinoma

Cellular components related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.02	CDKN1A CDX2 ESR1 PTGS2 TP53

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.8	CDKN2A EBAG9 KRT20 TP53 VIL1
2	negative regulation of cell growth	GO:0030308	9.63	CDKN1A CDKN2A TP53
3	cell cycle arrest	GO:0007050	9.46	CDKN1A CDKN2A RASSF1 TP53
4	negative regulation of phosphorylation	GO:0042326	9.43	CDKN1A CDKN2A
5	positive regulation of RNA polymerase II transcriptional preinitiation complex assembly	GO:0045899	9.37	ESR1 TP53
6	negative regulation of immature T cell proliferation in thymus	GO:0033088	9.32	CDKN2A ERBB2
7	signal transduction by p53 class mediator	GO:0072331	9.26	CDKN1A TP53
8	Ras protein signal transduction	GO:0007265	9.26	CDKN1A CDKN2A RASSF1 TP53
9	replicative senescence	GO:0090399	8.8	CDKN1A CDKN2A TP53

Molecular functions related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	9.26	ESR1 PGR PTGS2 TP53
2	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	8.62	CDKN1A CDKN2A

Sources

Sources for Cervical Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia